January 2021

Publications supported by LLS Research

In the month of January, we have identified 42 peer-reviewed publications that cited support from the Leukemia and Lymphoma Society through our various Research Grants programs!

 

We apologize if you are not featured on this list and you feel you should be - please e-mail your Program Lead or the Grant Administration Team at [email protected] to alert us to your new publication.

 

CDP

 

Career Development Program (CDP) grants support researchers early in their careers, from those with less than two years of postdoctoral research to those who hold independent faculty-level positions. The grants are designed to encourage these promising young investigators to embark on academic careers involving clinical or fundamental research in the blood cancers. This month, 13 peer-reviewed papers acknowledged our CDP grants program as a source of funding.

 

SCOR

 

The innovative Specialized Center of Research Program (SCOR) program funds teams of researchers from one or several institutions to engage in collaborative efforts to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants in order to discover new approaches to treating patients with blood cancers. We have found 10 peer-reviewed papers that were published in this month and they all acknowledged funding through LLS SCOR.

TRP

 

The Translational Research Program (TRP) funds new and innovative research that shows high promise of moving from laboratory discoveries to clinical application. In January 2021 we have identified 8 publications that cited support from our bench to bedside fast-track award program designed to help reduce the time between laboratory findings and actual treatment.

 

 

Discovery

 

The Blood Cancer Discoveries Grant Program (BCDG) is designed to encourage basic research, technological innovation, and informatics pipeline development that can lead to an understanding of blood cancer disease mechanisms, the development of improved methods for detecting and monitoring cancer progression, and the identification of novel therapeutic targets. This program opened last year and we have already seen 2 papers come out!

Special grants

We also fund blood cancer research through special Research grants and Mission initiatives. We have seen 3 papers that received funding through one of our special grants.

Mutiple grants

In addition to the above, there were 6 papers published this month that were supported through multiple grant programs.

TAP logo

Therapy Acceleration Program® (TAP) is a strategic venture philanthropy funding initiative to accelerate high-risk, innovative blood cancer therapeutics and change the standard of care in leukemia, lymphoma, and multiple myeloma. Several of our TAP partners presented new data during the 62nd ASH Annual Meeting and Exposition in December.

 

 

 

 

 

 

Publications citing support from a CDP award

 

Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, Jordan CT, Smith C, Gutman JA, Pollyea DA. The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia. Leuk Lymphoma. 2020 Dec 30:1-9.

Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, Adamia S, Zhu H, Kuang Y, Mogili A, Louissaint A Jr, Bohl SR, Kim AS, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, Weinstock DM, Garcia JS, Letai A. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020 Dec 14;38(6):872-890.e6.

Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020 Oct 1;105(10):2358-2367.

Lange PT, Damania B. Modeling oncogenic herpesvirus infections in humanized mice. Curr Opin Virol. 2020 Oct;44:90-96.

Yewdell WT, Kim Y, Chowdhury P, Lau CM, Smolkin RM, Belcheva KT, Fernandez KC, Cols M, Yen WF, Vaidyanathan B, Angeletti D, McDermott AB, Yewdell JW, Sun JC, Chaudhuri J. A Hyper-IgM Syndrome Mutation in Activation-Induced Cytidine Deaminase Disrupts G-Quadruplex Binding and Genome-wide Chromatin Localization. Immunity. 2020 Nov 17;53(5):952-970.e11.

Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, Rahmat M, Flaifel A, Ferland B, Su NK, Agius MP, Park J, Manier S, Bustoros M, Huynh D, Capelletti M, Berrios B, Liu CJ, He MX, Braggio E, Fonseca R, Maruvka Y, Guerriero JL, Goldman M, van Allen E, McCarroll SA, Azzi J, Getz G, Ghobrial IM. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020 May;1(5):493-506.

Zhao J, Bewersdorf JP, Jaszczur S, Kowalski A, Perreault S, Schiffer M, Gore S, Podoltsev N, Prebet T, Shallis R, Zeidan AM. High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. Leuk Lymphoma. 2020 Dec 16:1-13.

Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021 Apr;18(4):199-214.

Dai HQ, Hu H, Lou J, Ye AY, Ba Z, Zhang X, Zhang Y, Zhao L, Yoon HS, Chapdelaine-Williams AM, Kyritsis N, Chen H, Johnson K, Lin S, Conte A, Casellas R, Lee CS, Alt FW. Loop extrusion mediates physiological Igh locus contraction for RAG scanning. Nature. 2021 Feb;590(7845):338-343.

Demajo S, Albero R, Clot G, Castellano G, Navarro A, Capdevila C, Enjuanes A, Nadeu F, Giné E, Pinyol M, Jaffe ES, Ott G, Staudt LM, Rosenwald A, Scott DW, Rimsza LM, López-Guillermo A, Beà S, Campo E, Jares P. A Cyclin D1-Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clin Cancer Res. 2021 Jan 1;27(1):213-225.

Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31189-31197. 

Martinez-Høyer S, Karsan A. Mechanisms of lenalidomide sensitivity and resistance. Exp Hematol. 2020 Nov;91:22-31.

Orgel E, Nabais T, Douglas C, Mittelman SD, Neely M. Effect of Body Fat on Population Pharmacokinetics of High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia. J Clin Pharmacol. 2020 Dec 12.

Publications citing support from a SCOR award

 

Brinkmann K, Waring P, Glaser SP, Wimmer V, Cottle DL, Tham MS, Nhu D, Whitehead L, Delbridge AR, Lessene G, Smyth IM, Herold MJ, Kelly GL, Grabow S, Strasser A. BCL-XL exerts a protective role against anemia caused by radiation-induced kidney damage. EMBO J. 2020 Dec 15;39(24):e105561.

Chu CS, Hellmuth JC, Singh R, Ying HY, Skrabanek L, Teater MR, Doane AS, Elemento O, Melnick AM, Roeder RG. Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage. Mol Cell. 2020 Dec 3;80(5):845-861.e10.

Dhodapkar MV, Dhodapkar KM. Tissue-resident memory-like T cells in tumor immunity: Clinical implications. Semin Immunol. 2020 Jun;49:101415.

Kuhn NF, Lopez AV, Li X, Cai W, Daniyan AF, Brentjens RJ. CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. Nat Commun. 2020 Dec 2;11(1):6171.

Potts MA, McDonald JA, Sutherland KD, Herold MJ. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy. Eur J Immunol. 2020 Dec;50(12):1871-1884.

Rivas MA, Meydan C, Chin CR, Challman MF, Kim D, Bhinder B, Kloetgen A, Viny AD, Teater MR, McNally DR, Doane AS, Béguelin W, Fernández MTC, Shen H, Wang X, Levine RL, Chen Z, Tsirigos A, Elemento O, Mason CE, Melnick AM. Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. Nat Immunol. 2021 Feb;22(2):240-253.

Saint Fleur-Lominy S, Evensen NA, Bhatla T, Sethia G, Narang S, Choi JH, Ma X, Yang JJ, Kelly S, Raetz E, Harvey RC, Willman C, Loh ML, Hunger SP, Brown PA, Getz KM, Meydan C, Mason CE, Tsirigos A, Carroll WL. Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance. Cancer Res. 2020 Dec 1;80(23):5189-5202.

Driouk L, Gicobi JK, Kamihara Y, Rutherford K, Dranoff G, Ritz J, Baumeister SHC. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Front Immunol. 2020 Dec 15;11:580328.

Ha MJ, Kim J, Galloway-Peña J, Do KA, Peterson CB. Compositional zero-inflated network estimation for microbiome data. BMC Bioinformatics. 2020 Dec 28;21(Suppl 21):581.

Cheng Z, Cao Y, Ren J, Qin Y, Zhou Y, Jia Y, Gozani O, Patel DJ, Wang Z. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases. Nature. 2021 Feb;590(7846):498-503.

Publications citing support from a TRP grant

 

Borden KLB. The Nuclear Pore Complex and mRNA Export in Cancer. Cancers (Basel). 2020 Dec 25;13(1):42.

Daher M, Rezvani K. The evolution of NK cell immunotherapy for hematologic malignancies: A historical and contemporary perspective. Semin Hematol. 2020 Oct;57(4):165-166..

Daher, M., and Rezvani, K. Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer. Cancer Discov 11, 45-58.

Gbadamosi MO, Shastri VM, Hylkema T, Papageorgiou I, Pardo L, Cogle CR, Doty A, Loken MR, Meshinchi S, Lamba JK. Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms. Future Oncol. 2021 Jan;17(3):263-277.

Maura F, Landgren O, Morgan GJ. Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma. Clin Cancer Res. 2021 Jan 1;27(1):15-23. 

Miller PG, Sperling AS, Gibson CJ, Viswanathan K, Castellano C, McConkey M, Ceremsak J, Taylor MS, Birndt S, Perner F, Arnason J, Agrawal M, Schram AM, Nikiforow S, Pihan G, Hasserjian RP, Aster JC, La Rosée P, Morgan EA, Berliner N, Ebert BL. Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. Blood. 2020 Dec 24;136(26):3051-3055.

Ladds MJGW, Popova G, Pastor-Fernández A, Kannan S, van Leeuwen IMM, Håkansson M, Walse B, Tholander F, Bhatia R, Verma CS, Lane DP, Laín S. Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology. J Biol Chem. 2020 Dec 25;295(52):17935-17949.

Schonung, M., Meyer, J., Nollke, P., Olshen, A. B., Hartmann, M., Murakami, N., Wakamatsu, M., Okuno, Y., Plass, C., Loh, M. L., et al. (2021). International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia. Clin Cancer Res 27, 158-168.

Publications citing support from a Discovery award

 

Magee JA, Signer RA. Developmental stage-specific changes in protein synthesis differentially sensitize hematopoietic stem cells and erythroid progenitors to impaired ribosome biogenesis. Stem Cell Reports. 2021;16(1):20-28.

Jiang Q, Isquith J, Ladel L, Mark A, Holm F, Mason C, He Y, Mondala P, Oliver I, Reynoso E, Ma W, Ali S, Jamieson Morris I, Diep R, Pham J, Nasamran C, Xu G, Sasik R, Rosenthal SB, Birmingham A, Coso S, Pineda G, Crews L, Donohoe M, Venter JC, Whisenant T, Mesa RA, Alexandrov LB, Fisch KM, Jamieson C. Inflammation Driven Deaminase Deregulation Fuels Human Pre-leukemia Stem Cell Evolution. Cell Reports. 2021 Jan; 34(4).

Publications citing support for special grants

 

Basheer F, Vassiliou G. Mouse Models of Myeloid Malignancies. Cold Spring Harb Perspect Med. 2021 Jan 4;11(1):a035535. 

Matissek SJ, Han W, Karbalivand M, Sayed M, Reilly BM, Mallat S, Ghazal SM, Munshi M, Yang G, Treon SP, Walker SR, Elsawa SF. Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. Epigenomics. 2021 Jan;13(2):129-144.

Wang X, Huynh C, Urak R, Weng L, Walter M, Lim L, Vyas V, Chang WC, Aguilar B, Brito A, Sarkissian A, Bandara NA, Yang L, Wang J, Wu X, Zhang J, Priceman SJ, Qin H, Kwak LW, Budde LE, Thomas SH, Clark MC, Popplewell L, Siddiqi T, Brown CE, Forman SJ. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. Cancer Immunol Res. 2021 Jan;9(1):75-88.

Publications citing support for multiple grants

 

Chan, L. S. A., Gu, L. C., Leitch, H. A., and Wells, R. A. Intracellular ROS profile in hematopoietic progenitors of MDS patients: association with blast count and iron overload. Hematology 26, 88-95.

Miao H, Kim E, Chen D, Purohit T, Kempinska K, Ropa J, Klossowski S, Trotman W, Danet-Desnoyers G, Cierpicki T, Grembecka J. Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations. Blood. 2020 Dec 17;136(25):2958-2963.

Wen Z, Rajagopalan A, Flietner ED, Yun G, Chesi M, Furumo Q, Burns RT, Papadas A, Ranheim EA, Pagenkopf AC, Morrow ZT, Finn R, Zhou Y, Li S, You X, Jensen J, Yu M, Cicala A, Menting J, Mitsiades CS, Callander NS, Bergsagel PL, Wang D, Asimakopoulos F, Zhang J. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. Blood. 2021 Jan 7;137(1):61-74.

Gertz ML, Chin CR, Tomoiaga D, MacKay M, Chang C, Butler D, Afshinnekoo E, Bezdan D, Schmidt MA, Mozsary C, Melnick A, Garrett-Bakelman F, Crucian B, Lee SMC, Zwart SR, Smith SM, Meydan C, Mason CE. Multi-omic, Single-Cell, and Biochemical Profiles of Astronauts Guide Pharmacological Strategies for Returning to Gravity. Cell Rep. 2020 Dec 8;33(10):108429.

Malkani S, Chin CR, Cekanaviciute E, Mortreux M, Okinula H, Tarbier M, Schreurs AS, Shirazi-Fard Y, Tahimic CGT, Rodriguez DN, Sexton BS, Butler D, Verma A, Bezdan D, Durmaz C, MacKay M, Melnick A, Meydan C, Li S, Garrett-Bakelman F, Fromm B, Afshinnekoo E, Langhorst BW, Dimalanta ET, Cheng-Campbell M, Blaber E, Schisler JC, Vanderburg C, Friedländer MR, McDonald JT, Costes SV, Rutkove S, Grabham P, Mason CE, Beheshti A. Circulating miRNA Spaceflight Signature Reveals Targets for Countermeasure Development. Cell Rep. 2020 Dec 8;33(10):108448.

Roudko V, Bozkus CC, Orfanelli T, McClain CB, Carr C, O'Donnell T, Chakraborty L, Samstein R, Huang KL, Blank SV, Greenbaum B, Bhardwaj N. Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. Cell. 2020 Dec 10;183(6):1634-1649.e17.